Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

8.365
+0.0650.78%
Volume:2.13M
Turnover:17.73M
Market Cap:8.80B
PE:-19.34
High:8.510
Open:8.295
Low:8.135
Close:8.300
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.84
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.432
ROE:-28.59%
ROA:-19.64%
PB:3.32
PE(LYR):-19.34
PS:7953.28

Loading ...

Ascletis to Showcase ASC47, ASC36 and ASC35 Obesity Therapies at ECO 2026; Combo Trial Shows 111.8% Higher Relative Weight Loss vs. Semaglutide Alone

Bulletin Express
·
May 06

Ascletis reports Phase I data for ASC47 obesity drug at ECO 2026

Reuters
·
May 06

ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations

Stock News
·
Apr 30

ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions

Stock News
·
Apr 30

Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions

prnewswire
·
Apr 30

Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study

Reuters
·
Apr 30

歌礼制药-B(01672)2025年业绩:营收达0.02028亿元,净亏损3.5988亿元,三大管线研发推进

Bulletin Express
·
Apr 29

HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%

Tiger Newspress
·
Apr 28

Sagimet Biosciences Shares Rise With Focus on Acne Treatment

Dow Jones
·
Apr 27

ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes

Stock News
·
Apr 27

Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes

THOMSON REUTERS
·
Apr 27

Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30

Reuters
·
Apr 27

ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial

Stock News
·
Apr 24

HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%

Tiger Newspress
·
Apr 23

Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing

Simply Wall St.
·
Apr 18

ASCLETIS-B Nears Previous Peak, But Why Are Investors Staying on the Sidelines?

Stock News
·
Apr 18

ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials

Stock News
·
Apr 17

Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)

Simply Wall St.
·
Apr 09

ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant

Bulletin Express
·
Apr 08

ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment

Stock News
·
Apr 07